Rani Therapeutics (NASDAQ:RANI – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
Profitability
This table compares Rani Therapeutics and uniQure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rani Therapeutics | -493.00% | -76.64% | -56.97% |
| uniQure | -1,154.84% | -96.34% | -26.40% |
Volatility & Risk
Rani Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.
Insider and Institutional Ownership
30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations for Rani Therapeutics and uniQure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rani Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| uniQure | 1 | 3 | 11 | 1 | 2.75 |
Rani Therapeutics currently has a consensus target price of $8.33, indicating a potential upside of 1,483.38%. uniQure has a consensus target price of $56.83, indicating a potential upside of 138.70%. Given Rani Therapeutics’ higher probable upside, research analysts plainly believe Rani Therapeutics is more favorable than uniQure.
Valuation & Earnings
This table compares Rani Therapeutics and uniQure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rani Therapeutics | $1.63 million | 45.03 | -$29.67 million | ($0.19) | -2.77 |
| uniQure | $16.10 million | 103.73 | -$198.97 million | ($3.51) | -6.78 |
Rani Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
uniQure beats Rani Therapeutics on 8 of the 14 factors compared between the two stocks.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections. Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines.
About uniQure
uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
